Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;11(11):1549-1561.
doi: 10.1016/j.jchf.2023.06.031. Epub 2023 Aug 9.

Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction

Alessio Alogna  1 , Katlyn E Koepp  2 , Michael Sabbah  2 , Jair M Espindola Netto  3 , Michael D Jensen  4 , James L Kirkland  5 , Carolyn S P Lam  6 , Masaru Obokata  2 , Mark C Petrie  7 , Paul M Ridker  8 , Hidemi Sorimachi  2 , Tamara Tchkonia  3 , Adriaan Voors  9 , Margaret M Redfield  2 , Barry A Borlaug  10
Affiliations

Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction

Alessio Alogna et al. JACC Heart Fail. 2023 Nov.

Abstract

Background: Interleukin (IL)-6 is a central inflammatory mediator and potential therapeutic target in heart failure (HF). Prior studies have shown that IL-6 concentrations are elevated in patients with HF, but much fewer data are available in heart failure with preserved ejection fraction (HFpEF).

Objectives: This study aims to determine how IL-6 relates to changes in cardiac function, congestion, body composition, and exercise tolerance in HFpEF.

Methods: Clinical, laboratory, body composition, exercise capacity, physiologic and health status data across 4 National Heart, Lung, and Blood Institute-sponsored trials were analyzed according to the tertiles of IL-6.

Results: IL-6 was measured in 374 patients with HFpEF. Patients with highest IL-6 levels had greater body mass index; higher N-terminal pro-B-type natriuretic peptide, C-reactive protein, and tumor necrosis factor-α levels; worse renal function; and lower hemoglobin levels, and were more likely to have diabetes. Although cardiac structure and function measured at rest were similar, patients with HFpEF and highest IL-6 concentrations had more severely impaired peak oxygen consumption (12.3 ± 3.3 mL/kg/min 13.1 ± 3.1 mL/kg/min 14.4 ± 3.9 mL/kg/min, P < 0.0001) as well as 6-minute walk distance (276 ± 107 m vs 332 ± 106 m vs 352 ± 116 m, P < 0.0001), even after accounting for increases in IL-6 related to excess body mass. IL-6 concentrations were associated with increases in total body fat and trunk fat, more severe symptoms during submaximal exercise, and poorer patient-reported health status.

Conclusions: IL-6 levels are commonly elevated in HFpEF, and are associated with greater symptom severity, poorer exercise capacity, and more upper body fat accumulation. These findings support testing the hypothesis that therapies that inhibit IL-6 in patients with HFpEF may improve clinical status. (Clinical Trial Registrations: Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure [RELAX], NCT00763867; Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction, NCT02053493; Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF, NCT02742129; Inorganic Nitrite to Enhance Benefits From Exercise Training in Heart Failure With Preserved Ejection Fraction [HFpEF], NCT02713126).

Keywords: fat mass; heart failure with preserved ejection fraction; inflammation; interleukin-6; obesity.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Borlaug is supported by R01 HL128526, U01 HL160226, and R01 HL162828, from the National Institutes of Health (NIH), and W81XWH2210245, from the U.S. Department of Defense. Dr Alogna is supported by the Deutsche Forschungsgemeinschaft (DFG; CRC 1470, Z01). Drs Kirkland and Tchkonia are supported by R37 AG013925, P01 AG062413, and R33 AG061456 from NIH, the Connor Fund, Robert J. and Theresa W. Ryan, and the Noaber Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

FIGURE 1
FIGURE 1. Comparison of Exercise Capacity by IL-6 Level
As compared with patients with HFpEF and lower IL-6 levels, those with higher IL-6 levels displayed more severe impairments in exercise capacity, reflected both by lower 6MWD and peak VO2. Data from all 4 included trials, n = 374. 6MWD = 6-minute walk distance; HFpEF = heart failure with preserved ejection fraction; IL = interleukin; VO2 = oxygen consumption.
FIGURE 2
FIGURE 2. Comparison of Exercise Capacity and NT-proBNP by IL-6 Level Adjusted for BMI
(A) Linear regression analysis investigating the association between IL-6 levels and BMI. The tertiles of IL-6 relative to BMI-predicted values are represented in green (Tertile 1), orange (Tertile 2), and magenta (Tertile 3). (B) As compared with patients with IL-6 relative to predicted BMI in the lowest tertile, those in the highest tertile had lower peak VO2 and 6MWD, along with higher NT-proBNP. Data from all 4 included trials, n = 374. BMI = body mass index; NT-proBNP = N-terminal pro–B-type natriuretic peptide; other abbreviation as in Figure 1.
FIGURE 3
FIGURE 3. Comparison of Symptom Severity and Physical Limitations by IL-6 Level
As compared with patients with lower IL-6, patients with higher IL-6 levels displayed more severe symptoms of fatigue and dyspnea walking during the 2–2–5 treadmill walk test (A, B), and relative to exercise level during the maximal-effort upright cycling cardiopulmonary exercise test (C, D), along with poorer physical limitation scores from the SF-35 and KCCQ-Clinical Summary (CS) scores (E, F). Error bars not included to maximize clarity for C and D; SDs are provided in Table 2 for all distributions. Data from the INABLE trial, n = 52. CS = Clinical Summary; KCCQ = Kansas City Cardiomyopathy Questionnaire; 2–2–5 treadmill walk test = walking test at a gait speed of 2 miles per hour at a 2% grade for 5 minutes; other abbreviations as in Figures 1 and 2.
FIGURE 4
FIGURE 4. Body Composition, Adiposity, and IL-6
(A) DXA scans from patients with low (left) and high (right) IL-6 levels. (B) Fat mass index and its regional distribution in IL-6 tertiles. Patients with higher IL-6 levels had significantly greater total body fat mass index (kg/m2) compared with lower IL-6 patients. Differences in fat (kg/m2) were also observed within measurements of android/trunk, and lower limb regions between higher and lower IL-6 groups. Data from the INABLE trial, n = 52. DXA = dual-energy x-ray absorptiometry; other abbreviation as in Figure 1.
CENTRAL ILLUSTRATION
CENTRAL ILLUSTRATION. IL-6 Levels and Associated Clinical Characteristics in HFpEF
6MWD = 6-minute walk distance; BMI = body mass index; CRP = C-reactive protein; HFpEF = heart failure with preserved ejection fraction; IL = interleukin; NIH = National Institutes of Health; NT-proBNP = N-terminal pro-B-type natriuretic peptide; TNF = tumor necrosis factor; VO2 = oxygen consumption.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Murphy SP, Kakkar R, McCarthy CP, Januzzi JL Jr. Inflammation in heart failure: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:1324–1340. - PubMed
    1. Schiattarella GG, Rodolico D, Hill JA. Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc Res 2021;117:423–434. - PMC - PubMed
    1. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 2020;17:269–285. - PubMed
    1. Sanders-van Wijk S, Tromp J, Beussink-Nelson L, et al. Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF Study. Circulation 2020;142: 2029–2044. - PMC - PubMed
    1. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–271. - PubMed

Publication types

Associated data